Federated Hermes Inc. cut its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,004,369 shares of the company’s stock after selling 47,464 shares during the period. Federated Hermes Inc.’s holdings in Elanco Animal Health were worth $29,865,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of Elanco Animal Health by 15.6% in the 1st quarter. JPMorgan Chase & Co. now owns 355,004 shares of the company’s stock worth $9,262,000 after buying an additional 47,881 shares during the last quarter. American Century Companies Inc. grew its stake in Elanco Animal Health by 11.8% during the 1st quarter. American Century Companies Inc. now owns 32,218 shares of the company’s stock worth $841,000 after buying an additional 3,396 shares during the last quarter. US Bancorp DE increased its position in Elanco Animal Health by 17.5% in the first quarter. US Bancorp DE now owns 16,263 shares of the company’s stock worth $425,000 after buying an additional 2,419 shares during the period. Private Advisor Group LLC bought a new stake in Elanco Animal Health in the first quarter valued at $333,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Elanco Animal Health during the first quarter valued at $232,000. Institutional investors and hedge funds own 97.48% of the company’s stock.
Elanco Animal Health Price Performance
Shares of NYSE:ELAN opened at $12.95 on Friday. The stock has a market cap of $6.38 billion, a price-to-earnings ratio of -5.18, a PEG ratio of 1.42 and a beta of 1.29. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. Elanco Animal Health Incorporated has a 12 month low of $7.88 and a 12 month high of $16.88. The stock’s 50 day moving average price is $15.66 and its 200 day moving average price is $13.67.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm posted $0.19 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Stifel Nicolaus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and increased their price objective for the stock from $13.00 to $20.00 in a report on Friday, January 5th. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Morgan Stanley boosted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Barclays raised their target price on Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group boosted their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.
View Our Latest Research Report on Elanco Animal Health
Insider Buying and Selling at Elanco Animal Health
In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $16.14 per share, with a total value of $322,800.00. Following the purchase, the director now directly owns 185,000 shares of the company’s stock, valued at approximately $2,985,900. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.40% of the stock is owned by corporate insiders.
Elanco Animal Health Company Profile
(Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Articles
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.